MDGL insider sales: 1,336 shares on 03/06/2026

Madrigal Pharmaceuticals insider transaction notice (Form 144) The filing shows reported dispositions of Common Stock tied to an executive account and restricted stock unit vesting.

Rhea-AI Filing Summary

Madrigal Pharmaceuticals insider transaction notice (Form 144)

The filing shows reported dispositions of Common Stock tied to an executive account and restricted stock unit vesting. It lists two recent sales by Mardi Dier: 1,336 shares on 03/06/2026 for $586,958.24 and 1,183 shares on 03/02/2026 for $505,389.43. The document also records 646 shares associated with a Restricted Stock Unit vesting dated 03/06/2026, with an aggregate amount of $283,813.64 noted in the brokerage line.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions are reported for MDGL in this Form 144?

Two sales and an RSU vesting are reported. Mardi Dier sold 1,336 shares on 03/06/2026 for $586,958.24 and 1,183 shares on 03/02/2026 for $505,389.43; an additional 646 shares are listed tied to RSU vesting on 03/06/2026.

Who is the broker or filer listed on the MDGL Form 144?

Morgan Stanley Smith Barney LLC Executive Financial Services is listed as the broker/filing agent on the form, associated with the line showing 646 shares and an aggregate amount of $283,813.64 dated 03/06/2026.

How many shares did Mardi Dier sell in March 2026 according to the filing?

Reported sales total 2,519 shares in March 2026. The filing lists 1,183 shares sold on 03/02/2026 and 1,336 shares sold on 03/06/2026, with aggregate dollar amounts recorded alongside each transaction.

Are the reported RSUs in MDGL being sold or simply vesting?

The form identifies a Restricted Stock Unit grant and vesting event dated 03/05–03/06/2026. It lists 646 shares tied to the vesting; the entry appears under "Securities To Be Sold" and references the vesting as the operative event.

What dollar amounts are disclosed for the March 2026 insider sales in MDGL's Form 144?

Three aggregate amounts are shown. Sales by Mardi Dier list $505,389.43 (03/02/2026) and $586,958.24 (03/06/2026); a brokerage line tied to 646 shares shows $283,813.64 dated 03/06/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/06/2026 - 06:58 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001574591
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Madrigal Pharmaceuticals, Inc.
SEC File Number	001-33277
Address of Issuer	Four Towers Bridge 200 Barr Harbor Drive, Suite 200 West Conshohocken PENNSYLVANIA 19428
Phone	267-824-2827
Name of Person for Whose Account the Securities are To Be Sold	Mardi Dier
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza, 8th Floor New York NY 10004	646	283813.64	22939969	03/06/2026	Nasdaq Stock Market

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/05/2026	Restricted Stock Unit Grant	Issuer			646	03/06/2026	Vesting of Restricted Stock Units

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Mardi Dier c/o Madrigal Pharmaceuticals, Inc. 200 Barr Harbor Drive, Suite 200 West Conshohocken PA 19428	Common Stock	03/06/2026	1336	586958.24
Mardi Dier c/o Madrigal Pharmaceuticals, Inc. 200 Barr Harbor Drive, Suite 200 West Conshohocken PA 19428	Common Stock	03/02/2026	1183	505389.43

144: Remarks and Signature

Remarks	The sale of shares of common stock reported on this Form 144 represents the sale of shares pursuant to a sell-to-cover transaction in order to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units previously granted to the Reporting Person.
Date of Notice	03/06/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Mardi Dier
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)